Abstract
Patients who require intensive care are a uniquely vulnerable population. Their concurrent comorbidities, altered nutrition, required medications, and impaired barrier function predisposes them to a host of complications including nosocomial infections. Unfortunately, such intensive care unit-acquired infections are increasingly caused by resistant pathogens, further complicating their optimal care. As such, nonantibiotic prophylaxis and/or treatment strategies are particularly appealing in this subset of patients. An increasing amount of literature, both basic science and clinical in nature. suggests that probiotic, prebiotic, and synbiotic therapies may be effective in reducing nosocomial infection rates and the adverse implications of these infections. Although existing synbiotic studies in critically ill populations often suffer from small sample sizes and methodologic limitations, our current collective knowledge suggests that synbiotic therapy is safe and viable across an array of disease states. This review summarizes our current knowledge in this area, including limitations to our current investigations.
| Original language | English |
|---|---|
| Title of host publication | Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion |
| Publisher | Elsevier Inc. |
| Pages | 585-592 |
| Number of pages | 8 |
| ISBN (Electronic) | 9780128023716 |
| ISBN (Print) | 9780128021897 |
| DOIs | |
| State | Published - Oct 8 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Synbiotics in the Intensive Care Unit. / Mohammad, Diya; Morrow, Lee E.
Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion. Elsevier Inc., 2015. p. 585-592.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Synbiotics in the Intensive Care Unit
AU - Mohammad, Diya
AU - Morrow, Lee E.
PY - 2015/10/8
Y1 - 2015/10/8
N2 - Patients who require intensive care are a uniquely vulnerable population. Their concurrent comorbidities, altered nutrition, required medications, and impaired barrier function predisposes them to a host of complications including nosocomial infections. Unfortunately, such intensive care unit-acquired infections are increasingly caused by resistant pathogens, further complicating their optimal care. As such, nonantibiotic prophylaxis and/or treatment strategies are particularly appealing in this subset of patients. An increasing amount of literature, both basic science and clinical in nature. suggests that probiotic, prebiotic, and synbiotic therapies may be effective in reducing nosocomial infection rates and the adverse implications of these infections. Although existing synbiotic studies in critically ill populations often suffer from small sample sizes and methodologic limitations, our current collective knowledge suggests that synbiotic therapy is safe and viable across an array of disease states. This review summarizes our current knowledge in this area, including limitations to our current investigations.
AB - Patients who require intensive care are a uniquely vulnerable population. Their concurrent comorbidities, altered nutrition, required medications, and impaired barrier function predisposes them to a host of complications including nosocomial infections. Unfortunately, such intensive care unit-acquired infections are increasingly caused by resistant pathogens, further complicating their optimal care. As such, nonantibiotic prophylaxis and/or treatment strategies are particularly appealing in this subset of patients. An increasing amount of literature, both basic science and clinical in nature. suggests that probiotic, prebiotic, and synbiotic therapies may be effective in reducing nosocomial infection rates and the adverse implications of these infections. Although existing synbiotic studies in critically ill populations often suffer from small sample sizes and methodologic limitations, our current collective knowledge suggests that synbiotic therapy is safe and viable across an array of disease states. This review summarizes our current knowledge in this area, including limitations to our current investigations.
UR - http://www.scopus.com/inward/record.url?scp=84967335341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84967335341&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-802189-7.00043-5
DO - 10.1016/B978-0-12-802189-7.00043-5
M3 - Chapter
SN - 9780128021897
SP - 585
EP - 592
BT - Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion
PB - Elsevier Inc.
ER -